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Microﬂuidics-assisted multiplexed biomarker
detection for in situ mapping of immune cells
in tumor sections
Daniel Migliozzi 1, Benjamin Pelz1,2, Diego G. Dupouy2, Anne-Laure Leblond3, Alex Soltermann3 and Martin A. M. Gijs1
Abstract
Because of the close interaction between tumors and the immune system, immunotherapies are nowadays
considered as the most promising treatment against cancer. In order to deﬁne the diagnosis and the subsequent
therapy, crucial information about the immune cells at the tumor site is needed. Indeed, different types or activation
status of cells may be indicative for speciﬁc and personalized treatments. Here, we present a quantitative method to
identify ten different immuno-markers in the same tumor cut section, thereby saving precious samples and enabling
correlative analysis on several cell families and their activation status in a tumor microenvironment context. We
designed and fabricated a microﬂuidic chip with optimal thermomechanical and optical properties for fast delivery of
reagents on tissue slides and for fully automatic imaging by integration with an optical microscope. The multiplexing
capability of the system is enabled by an optimized cyclic immunoﬂuorescence protocol, with which we
demonstrated quantitative sequential immunostaining of up to ten biomarkers on the same tissue section.
Furthermore, we developed high-quality image-processing algorithms to map each cell in the entire tissue. As proof-
of-concept analyses, we identiﬁed coexpression and colocalization patterns of biomarkers to classify the immune cells
and their activation status. Thanks to the quantitativeness and the automation of both the experimental and analytical
methods, we believe that this multiplexing approach will meet the increasing clinical need of personalized diagnostics
and therapy in cancer pathology.
Introduction
Evidence of a close interaction between tumors and the
immune system has been reported for several typologies
of cancer: gastrointestinal1, ovarian2, lung3, and pancrea-
tic4 among others. Studies on the presence of immune
cells in the tumor microenvironment suggest their strong
interplay with the cancer cells5–8, and thus immu-
notherapies have been gaining much interest as effective
treatment against cancer3,9,10. In current clinical evalua-
tion of cancer severity, the activation status of the
immune system in the surroundings of the tumor site is a
key aspect to investigate11–18. To detect the presence of
speciﬁc cell types, the standard practice is to perform
straining on tissue slides from tumor biopsies by using
marker-speciﬁc antibodies19 (Abs). From the detection of
several cell types on the same tissue slide, oncologists can
gain information on the potential interaction between
them, which can be crucial to understand the interplay
between the immune system and the cancer cells. More-
over, because of the highly invasive procedure to obtain
tumor biopsies, staining for more than one biomarker on
a same tissue slide enables to save such rare and precious
samples.
Among the methods for multiplexed detection of mar-
kers on a same tissue slide, there are those, such as
spectral deconvolution with confocal imaging20 and
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tyramide signal-ampliﬁcation-based21,22, where the stain-
ing is performed for all the markers before the imaging
step. The main drawback of these methods is the limited
number of markers that can be detected simultaneously
(<10 even by using multispectral imaging). To overcome
this limit, methods such as staining with DNA-barcoded
Abs23,24, microﬂuidic compartmentalization combined
with quantum-dot labeling25, cyclic staining with ﬂuor-
escently labeled Abs alternated with chemical inactiva-
tion26 or elution27,28 have been developed. The last two
techniques also decrease the complexity of the assay by
not needing chemically modiﬁed Abs. The limit of che-
mical inactivation-based techniques is that they require
the primary Ab (that targets the marker to detect) to have
a ﬂuorescent tag, which prevents exploiting the signal-
ampliﬁcation beneﬁt of using an indirect staining (i.e.
untagged primary Ab+ tagged secondary Ab). Further-
more, the unavailability of conjugated primary Abs for
certain markers may prevent applicability or require an
additional chemical-labeling step. Cyclic-staining techni-
ques as described above allow the observation of >40
markers26,28. However, due to the need to perform many
staining cycles most of these techniques are very time
consuming and require intensive manual handling
because the slides have to be mounted and unmounted in
between staining cycles. Microﬂuidics have already been
proved suitable to standardize ﬂuorescent immunostain-
ing on tissue sections29–31. For these reasons, we aimed at
creating a microscope-integrated microﬂuidic platform to
perform fast, quantitative and automated multiplexing
and analysis of tissue sections for cancer immunology by
using elution-based microﬂuidics-assisted cyclic immu-
noﬂuorescence and image-based signal quantiﬁcation and
cell mapping. Important immune-cell families (and their
corresponding biomarkers) are T-lymphocytes (CD3),
cytotoxic T-lymphocytes (CD3, CD8), T helper lympho-
cytes (CD3, CD4), regulatory T-lymphocytes (CD3,
FOXP3, CD4, CD25), B-lymphocytes (CD20), macro-
phages (CD68, CD11b), and natural-killer cells (CD56).
Moreover, speciﬁc immune activation/inhibition can be
assessed (PD-1 and PD-L1) as well as the development
status (CD45RA for naïve and CD45RO for memory
immune cells). Therefore, we developed a microﬂuidic
multiplexing method for a selected subset of these mar-
kers (i.e. CD3, CD4, CD8, FOXP3, CD20, CD68, CD56,
PD-1, and PD-L1), as well as a marker used to identify
cells of epithelial origin (pan-Cytokeratins: CK), which
highlights carcinoma cells. Among these markers, there
are membrane, cytoplasmic and nuclear proteins, which
can appear very differently when detected by optical
imaging24,26. Therefore, to guarantee high-quality auto-
matic detection for all biomarkers, we developed custom
image-processing methods for each marker based on the
morphology of the positive-stained cells.
Results and discussion
The glass-cyclic oleﬁn copolymer microﬂuidic tissue
processor and the integration with the optical microscope
The immunoﬂuorescence stainings were performed
using an adapted design of a microﬂuidic technology
which has already been used to study cancer biomarkers
on clinical samples21,29,30,32–34 and cancer cell lines35,36.
The novel design of the microﬂuidic tissue processor
reported here includes the integration of an optical-grade
glass window in a cyclic oleﬁn copolymer (COC) element:
this enables direct microscopic observation of the tissue
slide through the microﬂuidic chip during the experi-
ment. Speciﬁcally, the present structure of the Look-
Through Chip is composed of: a microstructured COC
element that includes the microﬂuidic channels; an
optical-grade glass coverslip that constitutes the imaging
window; a gasket of polydimethylsiloxane (PDMS) that
forms the reaction chamber (height of ≈50 µm) on the
tissue slide. COC is a thermoplastics with attractive
optical, chemical and thermal properties: chemical
resistance to common solvents, high water barrier, low
moisture uptake, and high heat deﬂection tempera-
ture37,38. Moreover, it is an inert material that is not
contaminated by many chemicals used in clinical
pathology protocols, and it is thermo-mechanically
compatible with the fast heating/cooling of the sample
for steps that require to operate at speciﬁc temperatures.
Furthermore, the window made of an optical-grade glass
coverslip (thickness of 170 μm) enables the use of high
NA dry- or immersion-objectives, which require short
working distance and high optical purity for suitable
aberration correction. The design of the LTC with the
microﬂuidic channels, gasket and glass window is
depicted in Fig. 1a. The stainer (Fig. 1b) provides: the
support for the clamping between the LTC and the tissue
slide through pneumatic pistons; the temperature-
conditioning system including a resistance thermo-
meter, a Peltier element, and cooling-ﬁns; the connection
to the reagent delivery system; the support for the inte-
gration with the optical microscope. Such a system
enables fast delivery of the reagents to the reaction
chamber and precise temperature control: it takes less
than 30 s to heat up from room temperature to 37 °C (for
the staining steps) or from 37 to 50 °C (for the elution
steps). Different from previous stainers21,34, the
arrangement of microﬂuidic chip and microscope slide
placement is inverted to enable direct optical access to
the slide on an upright microscope through the LTC as
shown in Fig. 1a. Mounting the stainer on a regular
microscope stage of an upright microscope allows the
movement of the whole assembly of LTC and tissue slide
under the objective. This conﬁguration enables ﬂuor-
escent imaging by wide-ﬁeld scanning through the ima-
ging window (scanning area of 4 × 4 mm2) as well as
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performing fast staining cycles using the FFEX technol-
ogy without needing to remove the sample from the
microscope (Fig. 1c).
Fluorescence signal identiﬁcation and cell mapping
In order to evaluate the quality of the staining and to
map each cell on the tissue, we created high-throughput
computational algorithms that use the morphological
properties of the ﬂuorescence image of each biomarker to
identify the signal pixels and the location of the cells. For
ring-shape markers (CD3, CD4, CD8, CD56, CD20, and
PD-1), we exploited the ﬁxed thickness of the membrane
staining to perform a local analysis around each pixel to
enhance and threshold the local contrast of the image (see
Methods for more details). This sharpening method
enabled the selection of the signal pixel of the image,
which was then conﬁrmed by manual inspection by
experienced pathologists. The subsequent step includes
the computation of the ultimate eroded points of the
signal image (see Methods for more details), which
represent the approximate center of the cells (Fig. 2a). For
particle-shape markers (FOXP3 and CD68), both steps are
achievable with local contrast enhancement and thresh-
olding combined with watershed segmentation (Fig. 2a).
For cluster-shape markers (CK and PD-L1), for which the
morphology is much less deﬁned than for the other
markers, the signal identiﬁcation is based on attribute
ﬁltering and contrast thresholding, whereas the mapping
is not possible in this case due to a lack of deﬁned mor-
phology of the cells (Fig. 2a). We evaluated the perfor-
mance of the cell detection by manually assessing the
detected cells (DC), the false positives (FP), the true
positives (TP=DC− FP), and the false negatives (FN)
(i.e. FP= cells wrongly detected as being positive, FN=
cells wrongly detected as being negative) and by then
evaluating the sensitivity (TP/[TP+ FN]) and the preci-
sion (TP/[TP+ FP]) of the image-based detection
(Fig. 2b). The performance of the algorithms is very high,
with sensitivity and precision of about 90%, which could
represent a powerful means for oncologists when dealing
with large sample areas containing millions of cells that
would be impossible to analyze by direct visual inspection
at the single cell level.
Characterization of staining efﬁciency, elution efﬁciency
and epitope stability
Because of the advantages discussed previously, we used
indirect immunoﬂuorescent staining steps alternated with
Microscope
Microscope slide
with tissue
Staining chip
with window
Reagent delivery
system
Tissue pre
processing Staining Imaging Elution Imaging
10x
Staining time per marker 9–11 min; time for 10-plex 6.5 h
Pressurized piston Heating element
Staining chip
a b
c
Glass window
Gasket
On-chip + microscope-integrated
Holder for integration
with the microscope
Force of piston
Inlet
Outlet
Heating element
170 µm 50 µm
1 mm
PDMS gasket
Staining chip
30 mm
45 m
m
Microfluidic
channel design
Inlet
Outlet
Mechanical toggle
Fig. 1 Look-Through Chip (LTC) and stainer for integration with an optical microscope. a COC chip with microﬂuidic channels, a PDMS gasket
to create the reaction chamber on top of the tissue sample, and a glass coverslip to enable online imaging of the tissue slide. The exchange of
reagents is done in a timeframe of 1 s, following the principle of the fast-ﬂuidic exchange (FFEX) technology. b The LTC is mounted on the stainer
and clamped to the glass slide with the tissue by two air-pressure-driven pistons which apply force vertically as indicated by the arrow. It also
contains a heating element for precise control of the temperature of the chamber. Furthermore, the stainer can be mounted on a regular motorized
microscope stage, thereby enabling the scanning of the tissue slide when clamped with the LTC. c Tissue preprocessing (including dewaxing and
antigen retrieval) is performed off-chip. Subsequently, the slide is transferred to the stainer where staining, imaging and elution cycles are performed
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steps of elution. The staining conditions (Ab concentra-
tion and incubation time) are speciﬁc to each marker, but
the overall duration of the incubations is 2–4min for
primary Abs and 2 min for secondary Abs, which guar-
antees fast and quantitative immunoﬂuorescent staining,
as described previously29,35,36. The elution step is the
same for all the markers and consists in 2 min incubation
in elution buffer at 50 °C. We assessed the staining and
elution efﬁciency for all the markers of our panel inde-
pendently on inﬂamed tonsil sections, where the presence
of immune cells is guaranteed and can be used to robustly
test each step of the protocol (Fig. 3a). To evaluate the
ability to distinguish between signal and background, we
used the contrast-to-noise ratio CNR= (S− B)/ΔB, which
is a parameter calculated from the average signal gray
value (S), the average background gray value (B) and the
standard deviation of the background gray value (ΔB).
The CNR quantiﬁes how high the signal is relatively to the
background in terms of standard deviations of the latter,
and thus represents the likelihood that the detected signal
does not come from ﬂuctuations of the background. For
CNR > 2, more than two standard deviations separate
signal and background, which guarantees high distin-
guishability. Moreover, since cells that are positive for a
marker do not necessarily express the marker equally, the
“true signal” may also vary, which means that also the
CNR has a standard deviation that can be calculated (see
Methods for more details). In Fig. 3b we report the CNR
for each marker for several conditions. For the staining
step (Fig. 3b, green dots), all the markers resulted in CNR
> 2 for very short incubation time (Table S1). After the
elution step (Fig. 3b, red squares), there is no signal
remaining on the slide for any of the markers, thus
resulting in low CNR. Importantly, the CNR reported here
Sensitivity
(%)
Precision
(%)
CD3 94 91
CD4 94 87
CD8 93 87
FOXP3 97 90
PD-1 95 91
CD56 82 87
CD20 97 88
CD68 96 98
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Fig. 2 Image processing for signal identiﬁcation and cell mapping. a Outcomes for ring-shape markers (CD4 in the image), particle-shape
markers (FOXP3 in the image) and cluster-shape markers (CK in the image). Red outlines and dots indicate the border and the center of the cells
automatically detected by the algorithm. Arrows indicate the cells that were missed by the algorithm Scale bars, 25 μm. b Quality-of-detection
parameters resulting from the cell mapping
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for the elution step is measured after re-staining with
secondary Abs alone: this was done to demonstrate that
the elution step not only removed the labeled secondary
Abs, but also the unlabeled primary Abs. Finally, to
evaluate the effect of the elution steps on the stability of
the epitope, we performed a staining step (primary and
secondary Abs) after several cycles of elution (ﬁve for PD-
1, CD8, CK, CD4, CD3, and ten for FOXP3, CD68, PD-L1,
CD56, and CD20). Figure 3b, c (brown diamonds) shows
that detectability is preserved for all the markers except
PD-1.
Automated microﬂuidic multiplexing on tissue sections
Based on these single-biomarker results, we established
that PD-1 should be stained at the beginning of the
multiplexing protocol, because its staining signal decrea-
ses after elution. The other markers can be stained
without loss of quality for all the elution cycles tested: ﬁve
for CD8, CK, CD4, and CD3; ten for FOXP3, CD68, PD-
L1, CD56 and CD20. Based on such considerations, we
have chosen the following order: PD-1, CD8, CK, CD4,
CD3, FOXP3, PD-L1, CD56, and CD20. This order
guarantees that all the markers exhibit sufﬁcient CNR to
be detected at the right step of the multiplexing, and
complete removal before staining the following marker. In
a ﬁrst step the autoﬂuorescence of the tissue is recorded
for the AF647 channel which is later used to subtract the
autoﬂuorescence from the images of the markers. The full
staining of the individual markers including washing steps
took 9−11 min, depending on the incubation time of the
primary Ab. After each staining, the slide is imaged,
subsequently undergoes the elution process and a ﬁnal
imaging step for control purposes. Compared to con-
ventional immunostaining, where a single marker can
take up to several hours to be stained and imaged, our
method allows 10-plex staining including all imaging
steps in less than 7 h. In Figs. 4 and S5, we compare the
results of the microﬂuidic multiplex IF with conventional
single-plex chromogenic immunohistochemistry (IHC),
the current standard in clinical pathology. IF images with
the corresponding IHC controls on adjacent tonsils
(Fig. 4a) and lung cancer (Fig. S5) slices show that the
biomarker patterns are conserved in the microﬂuidic
elution-based multiplexing. CD3, CD4, CD8, CD20, CD56
and PD-1 show the ring-shape staining typical of markers
widely expressed on the cell membrane. CD68 appears as
puncta in cells positive for this marker. FOXP3, which
stains a transcriptional regulator with nuclear localization,
appears as a round particle. CK is a cytoskeleton protein
and marks the cytoplasm of epithelial cells. PD-L1 is a
transmembrane protein and can appear as clusters
(Fig. 4a) or puncta (Fig. S4b). In order to quantitatively
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compare the two methods, we used the fraction of stained
area (Fig. 4b). Concordance between conventional IHC
and microﬂuidic multiplexed staining is observed for both
tonsils and lung adenocarcinoma sections.
Proof-of-concept analyses on coexpression and
colocalization of biomarkers
We took advantage of having all the markers on the
same tissue slide to perform proof-of-concept
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Fig. 4 Automated microﬂuidics-assisted quantitative multiplexing. a Fluorescence images of biomarkers in tonsils from microﬂuidic 10-plex IF
and bright-ﬁeld images of conventional single-plex IHC on adjacent slides. Scale bars: 100 µm (overview images) and 15 µm (insets). b Comparison of
the stained area fraction from microﬂuidic multiplex IF and manual single-plex IHC for each marker. The correlation coefﬁcient r and its p value are
reported in the same graph
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coexpression and colocalization analysis on clinically
relevant questions. As a ﬁrst example, the importance of
identifying the T lymphocyte subtypes (Fig. 5a) in the
tumor microenvironment is crucial to efﬁciently address
diagnosis and immunotherapy2,4,14,16,18. For this reason,
we aimed at identifying the CD3+ cells (T lymphocytes)
which also expressed CD4 (T helper lymphocytes), CD8
(cytotoxic T lymphocytes), or FOXP3 (regulatory T lym-
phocytes) in a lung cancer section (4 × 4mm2). To per-
form this step, we used our cell mapping algorithm to
identify the positive cells for each marker (Fig. 5b), and
subsequently identiﬁed the double-positive cells by con-
sidering their proximity as detailed in the Methods-Data
analysis section. In Fig. 5c we report the number of cells
for each cell type. We observe that almost half (≈48%) of
the T lymphocytes present in this section are T helper
lymphocyte, but that also cytotoxic (≈11%) and regulatory
(≈13%) T lymphocytes are present in the tumor micro-
environment. Another fundamental aspect of T lympho-
cytes is their ability to be inhibited via speciﬁc signaling,
such as the PD-1/PD-L1 pathway10,39,40: PD-1 is a mem-
brane protein that can downregulate the immune system
by suppressing T lymphocyte inﬂammatory activity when
binding its ligand PD-L1, another membrane protein that
can be expressed in cancer cells, macrophages and other
cells. By using the same coexpression methodology as
previously, we identiﬁed the PD-1+T lymphocytes and
the PD-L1+macrophages in the same lung cancer case.
Figure 6a reports the number of cells detected and Fig. 6b
reports some clichés to illustrate colocalization of markers
and cells. We also observed that only a minority of T
lymphocytes express PD-1 in this lung tissue (≈3%), and
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Fig. 5 Proof-of-concept coexpression analysis on lung adenocarcinoma: T-cell phenotyping. a Schematics of T-cell differentiation with their
expressed biomarkers. b Fluorescence images of biomarkers in a tissue section of lung adenocarcinoma. Colored dots in the third image are the
detected cells for each biomarker. Colored arrows indicate cytotoxic (CD3+/CD8+, green), helper (CD3+/CD4+, yellow) and regulatory (CD3+/CD4+/
FOXP3+) T lymphocytes. Scale bars, 30 μm. c Number of cells detected on the tissue section per each T lymphocyte type. Error bars indicate the
predicted range for the true value of the number of cells, and are calculated based on sensitivity and precision reported in Fig. 1b
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similarly occurs for PD-L1 on macrophages (≈8%). As it
was reported that proximity of immune cells to PD-L1+
cells may have an impact on PD-1-targeted therapy41, we
calculated the center-to-center distance of each T-
lymphocyte from the closest PD-L1+ and CK+ cells
(Fig. 6c), to assess potential interaction between them.
Given the accuracy of the cell-mapping algorithm for the
localization of cells (see Methods for more details), CD3+
cells located closer than ≈5 μm to a CK+ cell are poten-
tially in contact with it (green region in Fig. 6c). Similarly,
PD-1+ T cells which are closer than ≈5 μm to a PD-L1+
cell have higher chance to be in contact with those cells
(gray region in Fig. 6c). This way, one can estimate the
likelihood of anticancer action or immune-cell inhibition,
respectively. We can observe that in the imaged area (4 ×
4mm2), about 1/3 of the PD-1+ T cells (orange dots in
Fig. 6c) may act as inhibitors for the immune reaction at
the tumor site.
Conclusion
The increasing need of multimarker detection and
analysis in current clinical contexts makes it necessary to
speed up and automate experimental and analytical
techniques to help pathologists obtain quantitative
information from precious samples such as tissue biop-
sies. We developed a microﬂuidic tissue processor that
combines fast and quantitative immunoﬂuorescent
staining with the ability to image the tissue slide without
the need to remove the microﬂuidic chip. The chip itself is
composed of a microstructured polymeric part in COC,
which has good mechanical and thermal properties that
enable to rapidly vary the temperature during the protocol
without harsh mechanical stress, while being inert to most
chemicals used in such assays. A glass coverslip glued on
the polymeric chip creates the ceiling of the microﬂuidic
chamber and gives the optimal optical properties for
ﬂuorescence imaging, performed with a system that is
fully integrated with an optical microscope. Overall, the
microﬂuidic-based approach combined to the integration
with the microscope for direct imaging after each step
enables to perform a 10-plex staining in less than 7 h
including all imaging steps. A comparable assay per-
formed with traditional methods including mounting and
unmounting for ﬂuorescence imaging for each marker
would require multiple days. Furthermore, we developed
image-based cell mapping by using morphological prop-
erties of the different markers. The quality-of-detection
parameters resulting from this procedure are very high
(≈93% sensitivity and ≈90% precision for all the markers).
Finally, coexpression and colocalization patterns were
explored in proof-of-concept analyses on a lung cancer
case. Further decrease of the experimental duration can
be achieved by staining and imaging multiple markers in
each cycle, e.g. by using a mouse and a rabbit primary
antibody in combination with two secondary antibodies
with different ﬂuorescent labels. Also, the inclusion of the
mapping for the cluster-shape markers can result from
further analysis on their morphology. Due to sequential
nature of the cyclic multiplexing, it would be easily pos-
sible to further increase the number of markers in the
multiplex staining. This would allow better classiﬁcation
of speciﬁc cell lineages (for instance CD25 and CD11b
would help in identifying regulatory T cells and macro-
phages, respectively) or the study of other immune
checkpoint markers such as LAG-3 or TIM-3. None-
theless, care has to be taken when adding new markers to
the multiplexing panel, a full characterization including
elution efﬁciency and epitope stability during elution
should be performed. In fact, some epitopes may be
particularly sensitive to the elution procedure42,43 (such as
the one targeted by the anti-PD-1 Ab in this study): the
low pH and the detergent may in fact affect the structure
of the epitope, which will not be recognized by the Ab any
more. This is an Ab-speciﬁc behavior, and previous stu-
dies reported this effect for epitopes of other markers42.
However, this highly depends on the epitope itself and
one should be careful in the choice of the Abs targeting
particularly sensitive ones. Alternatively, different elution
buffers or working temperatures may be explored. All in
all, the microscope integrated cyclic immunoﬂuorescence
technique greatly facilitates the execution of high-plex
stainings and thereby the discovery of novel tumor
−microenvironment interactions.
Methods
Materials
Formalin-ﬁxed parafﬁn-embedded (FFPE) slides for
protocol characterization were purchased from East West
Biopharma. They consisted of tonsils sections with
chronic tonsillitis (4 μm thickness). FFPE slides for mul-
tiplexed detection were provided by the Institute of
Pathology and Molecular Pathology, University Hospital
Zurich, and consisted of 2-μm-thick sections of inﬂamed
tonsils and lung adenocarcinoma. Tris buffered saline
(TBS) 10× and Tween20 were purchased from Sigma (No.
BP2471 and BP337-500). TBS 1× was obtained by diluting
the concentrated TBS stock in deionized water. For
immunostaining, the information about the antibodies are
detailed in SI Table 1. Target Retrieval Solution (TRS)
citrate pH 6, 10× was purchased from Dako (Code
S169984). TRS was obtained by diluting the concentrated
TRS stock in deionized water. Information about the
primary Abs is found in the SI. Secondary Abs were
purchased from Thermo Fisher Scientiﬁc: goat anti-
mouse IgG labeled with Alexa Fluor Plus 647 (code
A32728); goat anti-rabbit IgG labeled with Alexa Fluor
Plus 647 (code A32733). Abs were diluted in TBS-0.05%
Tween20 for the staining. The elution buffer consisted of
Migliozzi et al. Microsystems & Nanoengineering            (2019) 5:59 Page 9 of 12
IgG elution buffer pH 2.0 (Thermo Scientiﬁc, code 21028)
and 1% sodium dodecyl sulfate solution (SDS) (Fisher
Scientiﬁc, code BP1311-1). For reducing autoﬂuorescence
a 50mM ammonium acetate buffer (Sigma-Aldrich, code
09691) with 10 mM CuSO4 (Sigma-Aldrich, code
1027841000) was used. Imaging buffer consisted of 1×
TBS with 10mM sodium ascorbate (Sigma Aldrich,
A7631).
Tissue slides preparation
Tissue slides were dewaxed twice with Histoclear II
solution (National Diagnostics, USA) for 10min and 30 s
respectively. Then, they are rehydrated with a gradual
ethanol series of 100, 100, 95, 70, 40%, for 10 s each before
transferring the slides into tap water. Subsequently, anti-
gen retrieval is performed at 95 °C for 40min in Target
Retrieval Solution 1×, and then stored in TBS 1× until
staining. Alternatively, antigen retrieval was performed
using a whole-polymer microﬂuidic chip (identical to the
one of the multiplexing but with an opaque polymeric
window) at temperatures over 100 °C for 10min.
Chip fabrication
The microﬂuidic channels were micro-milled in a 1-
mm-thick COC sheet and a window of 8 × 8mm2 was cut
out in the center of the chip. #1.5 high precision glass
coverslips (Carl-Roth, Germany) were cut to the right
shape using a diamond tip pen and glued to the micro-
ﬂuidic chip by using UV-curable glue (NOA86, Norland,
USA). The window allows to image a ﬁeld of view of 4 ×
4mm2 of the tissue slide.
Microﬂuidic setup
Glass slides with the manually preprocessed tissue
sections were loaded into the stainer (Fig. 1b) which holds
the look-through chip. The chip is interfaced with the
slide via an elastomeric gasket forming a chamber of
reaction of 17 × 17mm2 with a height of ≈50 µm. The
reagents are delivered into the chamber in a sequential
manner as described previously29. The reagent delivery
system consists of several reservoirs (50 and 2 mL volume)
that can be used to deliver the reagents to the chip by
pressure-driven ﬂow. A graphical user interface on a
computer allows the control of all steps including the
imaging steps.
Optical imaging
Images were acquired using an AxioImager M2m
motorized epiﬂuorescence microscope (Zeiss, Germany)
with a ×20 0.8NA air objective. Zeiss ﬁlter cubes 02 and
50 were employed for DAPI and AF647 ﬂuorophores,
respectively, together with an X-Cite 120Q light source
(Excelitas, USA). Slides were either mounted with a cov-
erslip and Prolong Gold antifade mountant (Thermo
Fisher, USA) or imaged directly through the LTC
mounted on the stainer. If the imaging is performed
directly through the LTC, the chamber was ﬁlled with
imaging buffer to prevent the formation of radicals.
Exposure times were set depending on the staining
intensity and ranged between 30 and 500 ms. For the
automated staining and imaging, the microscope was
controlled using MicroManager 1.444 and the image
acquisition was started through the Matlab API. After
scanning, tiles were stitched using Axiovision or FIJI
software45. Brightﬁeld images were acquired with a
3DHistech Pannoramic Midi II slide scanner using a Zeiss
×20 0.8NA objective.
Image processing
Image processing is performed with FIJI. Independently
from the morphology of the marker, the autoﬂuorescence
image (taken before any staining) is subtracted from the
ﬂuorescence image of each marker, in order to remove the
nonspeciﬁc signal of the tissue. Then, a speciﬁc procedure
is applied depending on the type of marker.
For ring-shape markers, the following steps are per-
formed: a ﬁltered version of the ﬂuorescence image
(Gaussian ﬁlter with 2-pixel radius) is subtracted to the
raw image to enhance the local contrast; the local contrast
(local maximum – local minimum) is calculated for each
pixel by deﬁning its neighborhood as a disk of 3 pixel
radius; the pixels having both their local contrast higher
than the deﬁned threshold and their raw value higher than
the deﬁned mid-gray threshold are classiﬁed as SIGNAL;
the complementary of the SIGNAL is classiﬁed as
BACKGROUND after a 1-pixel erosion step, to avoid
potential misclassiﬁcation of pixels at the boundary
between SIGNAL and BACKGROUND; the SIGNAL
mask is then inverted and the ultimate eroded points
(UEPs) calculated; the UEPs with a value lower than 5 are
classiﬁed as detected cells and a CELL mask is created.
For particle-shape markers, the following steps are
performed: a morphological closing (Disk ﬁlter with 2-
pixel radius) is applied to the ﬂuorescence image; a
morphological white-top-hat ﬁlter (Disk ﬁlter with 15-
pixel radius) is applied to the resulting image; the pixels
having their value higher than the deﬁned threshold are
classiﬁed as SIGNAL; the complementary of the SIGNAL
is classiﬁed as BACKGROUND after a 1-pixel erosion
step, to avoid potential misclassiﬁcation of pixels at the
boundary between SIGNAL and BACKGROUND; the
SIGNAL mask is segmented by binary watershed; all
connected regions within a range of sizes (dependent on
the marker) are classiﬁed as detected cells and a CELL
mask is created.
For cluster-shape markers, the following steps are per-
formed: a median ﬁlter is applied to the ﬂuorescence
image (Disk ﬁlter with 1-pixel radius); a gray-scale
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opening ﬁlter (30-pixel area) is applied to the resulting
image; local Bernsen thresholding (radius= 5 pixels;
contrast= 100) is applied to deﬁne the SIGNAL pixels;
the complementary of the SIGNAL is classiﬁed as
BACKGROUND after a 1-pixel erosion step, to avoid
potential misclassiﬁcation of pixels at the boundary
between SIGNAL and BACKGROUND.
The signal and background quantiﬁcation is performed
on the raw images of the markers by using the SIGNAL
and BACKGROUND marks.
The standard deviation of the contrast-to-noise ratio is
calculated as the square root of the pooled variance of
SIGNAL and BACKGROUND divided by the standard
deviation of the background:
ΔCNR ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
NSΔS2 þ NBΔB2ð Þ= NS þ NBð Þ
p
ΔB
;
where NS and NB are the number of SIGNAL and
BACKGROUND pixels, respectively.
For IHC images, the following steps are performed:
color deconvolution for hematoxylin and diaminobenzi-
dine (DAB) staining is applied by using FIJI’s built-in
color deconvolution tool with H DAB color vector; sub-
sequently, the DAB image is inverted and thresholded to
deﬁne the SIGNAL pixels; the complementary of the
SIGNAL is classiﬁed as BACKGROUND after a 1-pixel
erosion step, to avoid potential misclassiﬁcation of pixels
at the boundary between SIGNAL and BACKGROUND.
Conventional immunohistochemistry and cyclic
immunoﬂuorescence on-chip
For chromogenic IHC, serial cuts were fully processed
in the conventional Ventana BENCHMARK platform
according to the manufacturer’s instructions. Information
on the primary Abs are reported in the supplementary
information. For the secondary Ab and detection via DAB,
the Optiview DAB kit (#760–700, Ventana) was used.
Sections were then counterstained with hematoxylin,
covered with coverslip and scanned for imaging analysis.
For cyclic IF on-chip, the following steps were per-
formed for each marker of the multiplexing panel: stain-
ing, imaging, elution and imaging (see Fig. 1c). The
autoﬂuorescence of the tissue was recorded before start-
ing the ﬁrst staining of the multiplexing. For the staining
of an individual marker, mouse or rabbit primary anti-
bodies were incubated for either 2 or 4 min (see SI).
Fluorescently labeled secondary Abs were incubated for
2 min. Total duration of the staining of a single marker
was between 9 and 11min. Imaging was performed as
described below. For the elution the tissue was incubated
with elution buffer at 50 °C for 2 min before being washed
with TBS. A second round of imaging was performed as
control for elution performance (see supplementary
information). The tissue was incubated with 10mM
CuSO4 in 50 mM ammonium acetate for 15 s after each
elution step to reduce the autoﬂuorescence of ery-
throcytes46. After the staining-imaging-elution-imaging
cycle was ﬁnished for one marker, the same cycle was
repeated for the next marker until all markers were
stained and imaged.
Data analysis
Coexpression and colocalization analyses are performed
with FIJI and MATLAB47. To determine coexpression of
two markers in the same cell, we select all the cells which
are positive for the two markers independently and we
selected the double-positive ones based on the precision of
the calculation of the cell location during the cell mapping
step: as the cell center is located with 3–4 pixels precision (≈
2–2.5 μm) and the cell size is about 14–15 pixels (≈10 μm),
centers of cells positive for two different markers and
located less than 5 pixels apart (≈3 μm) are indeed the same
cell, being positive for both markers. To perform this, the
following steps are performed: the CELL masks of the two
markers are enlarged by two pixels; all regions of overlap
are classiﬁed as cells being positive for coexpression.
For the colocalization analysis, we created a mask for
PD-L1 and CK by selecting all the pixels identiﬁed as
signal in the corresponding ﬂuorescence images. Then, we
calculated the minimum distance between each T lym-
phocyte and the PD-L1+ and CK+ regions. Due to the
same consideration as previously about the precision of
cell localization, cells located at less than 5 μm from PD-
L1+ or CK+ regions are potentially in contact with them.
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